We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?
Read MoreHide Full Article
Key Takeaways
BrightSpring Health Services' acute infusion volume grew more than 20% year over year in Q2.
Management targets 12-15 additional states over five years to drive market-share gains.
Investments in service levels, infrastructure, AI-enabled intake and analytics support expansion.
BrightSpring Health Services’ (BTSG - Free Report) acute infusion business is emerging as a meaningful growth engine, with volume increasing more than 20% year over year in the second quarter. According to management, this implies roughly 7-8x the growth rate of the overall infusion market. The company estimates the addressable infusion market at approximately $20 billion.
BTSG described the market as highly fragmented, with competition less intense on the acute side because of the demanding service-delivery requirements. This combination of a large market, fragmentation and relatively favorable competitive dynamics provides BTSG with considerable runway to gain share.
The key question is whether BTSG can sustain this above-market trajectory as its current footprint matures. Management believes the opportunity extends well beyond the company’s existing markets, identifying 12 to 15 additional states it plans to enter over the next five years. It believes that volume gains are likely to continue on the back of market-share capture rather than simply underlying industry growth.
This stronger-than-market growth is likely to be driven by the acute infusion business’s more attractive competitive environment and geographic expansion. Management also attributed the recent performance to operational initiatives, service levels and growth investments, indicating that execution, rather than favorable market conditions alone, is contributing to the acceleration.
BTSG continues to invest in the infrastructure required to scale its platform. On the chronic care side, management cited investments in capabilities, infrastructure, AI-enabled intake, commercial talent and data analytics, while also integrating purchasing and payer capabilities with its broader Pharmacy for America business. Although these investments primarily relate to the broader Infusion platform, they demonstrate BTSG’s willingness to invest ahead of growth.
With a $20 billion fragmented market, more than 20% acute-volume growth and a pipeline of 12-15 new states, BTSG appears positioned to compound share gains. The durability of those gains will ultimately depend on its ability to replicate service quality and operational execution as the footprint expands.
Peer Updates
Infusion remains the core growth engine for Option Care Health (OPCH - Free Report) , with acute therapy delivering another quarter of high-single-digit organic revenue growth, outpacing broader industry growth. The company reported sequential and year-over-year increases across key acute therapeutic categories and patient volumes, while chronic infusion also improved sequentially, led by IG/neuro and stabilization in chronic inflammatory therapies.
OPCH is expanding its ambulatory infusion footprint, adding five facilities in the second quarter, with clinic visits rising more than 20% year over year. Management expects acute to continue growing faster than the industry as hospital partnerships deepen. Longer term, broader Medicare coverage for home infusion and an expanding therapy portfolio offer additional upside.
Addus HomeCare’s (ADUS - Free Report) growth continues to be driven by its core home-based care businesses. Personal Care revenues increased 6.8% organically, supported by 2.2% growth in same-store hours, while hospice revenues rose 11.1% organically, with average daily census increasing 6.5% to 3,964 and surpassing 4,000 in July.Home health remained weaker but improved sequentially across revenues, operating income and admissions. The outlook centers on continued census growth, geographic expansion, acquisitions and stronger demand for home-based care, rather than infusion.
BTSG’s Price Performance, Valuation and Estimates
Shares of BTSG have surged 64% year to date compared with the industry’s 3.1% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, BrightSpring Health Services trades at a forward price-to-earnings ratio of 28.99X, above the industry average. It is also trading higher than its three-year high of 21.97X. BTSG carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BrightSpring Health Services’ 2026 earnings implies an 82% rise from the year-ago period’s level.
View the Zacks #1 Rank List
Image: Bigstock
Can BTSG Outgrow the $20B Acute Infusion Market on Volume Growth?
Key Takeaways
BrightSpring Health Services’ (BTSG - Free Report) acute infusion business is emerging as a meaningful growth engine, with volume increasing more than 20% year over year in the second quarter. According to management, this implies roughly 7-8x the growth rate of the overall infusion market. The company estimates the addressable infusion market at approximately $20 billion.
BTSG described the market as highly fragmented, with competition less intense on the acute side because of the demanding service-delivery requirements. This combination of a large market, fragmentation and relatively favorable competitive dynamics provides BTSG with considerable runway to gain share.
The key question is whether BTSG can sustain this above-market trajectory as its current footprint matures. Management believes the opportunity extends well beyond the company’s existing markets, identifying 12 to 15 additional states it plans to enter over the next five years. It believes that volume gains are likely to continue on the back of market-share capture rather than simply underlying industry growth.
This stronger-than-market growth is likely to be driven by the acute infusion business’s more attractive competitive environment and geographic expansion. Management also attributed the recent performance to operational initiatives, service levels and growth investments, indicating that execution, rather than favorable market conditions alone, is contributing to the acceleration.
BTSG continues to invest in the infrastructure required to scale its platform. On the chronic care side, management cited investments in capabilities, infrastructure, AI-enabled intake, commercial talent and data analytics, while also integrating purchasing and payer capabilities with its broader Pharmacy for America business. Although these investments primarily relate to the broader Infusion platform, they demonstrate BTSG’s willingness to invest ahead of growth.
With a $20 billion fragmented market, more than 20% acute-volume growth and a pipeline of 12-15 new states, BTSG appears positioned to compound share gains. The durability of those gains will ultimately depend on its ability to replicate service quality and operational execution as the footprint expands.
Peer Updates
Infusion remains the core growth engine for Option Care Health (OPCH - Free Report) , with acute therapy delivering another quarter of high-single-digit organic revenue growth, outpacing broader industry growth. The company reported sequential and year-over-year increases across key acute therapeutic categories and patient volumes, while chronic infusion also improved sequentially, led by IG/neuro and stabilization in chronic inflammatory therapies.
OPCH is expanding its ambulatory infusion footprint, adding five facilities in the second quarter, with clinic visits rising more than 20% year over year. Management expects acute to continue growing faster than the industry as hospital partnerships deepen. Longer term, broader Medicare coverage for home infusion and an expanding therapy portfolio offer additional upside.
Addus HomeCare’s (ADUS - Free Report) growth continues to be driven by its core home-based care businesses. Personal Care revenues increased 6.8% organically, supported by 2.2% growth in same-store hours, while hospice revenues rose 11.1% organically, with average daily census increasing 6.5% to 3,964 and surpassing 4,000 in July.Home health remained weaker but improved sequentially across revenues, operating income and admissions. The outlook centers on continued census growth, geographic expansion, acquisitions and stronger demand for home-based care, rather than infusion.
BTSG’s Price Performance, Valuation and Estimates
Shares of BTSG have surged 64% year to date compared with the industry’s 3.1% growth.
Image Source: Zacks Investment Research
From a valuation standpoint, BrightSpring Health Services trades at a forward price-to-earnings ratio of 28.99X, above the industry average. It is also trading higher than its three-year high of 21.97X. BTSG carries a Value Score of C.
Image Source: Zacks Investment Research
The Zacks Consensus Estimate for BrightSpring Health Services’ 2026 earnings implies an 82% rise from the year-ago period’s level.
Image Source: Zacks Investment Research
The stock currently sports a Zacks Rank #1 (Strong Buy). You can see the complete list of today’s Zacks #1 Rank stocks here.